Stocktoria

AbCellera Biologics Inc. ABCL

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2020-12-11 · LEI

AbCellera Biologics Inc. statistics & valuation

Market cap$2.3B
P / S30.0×
P / B2.3×
Net margin-194.9%
Return on equity-15.1%
FCF margin-231.7%
Return on capital-16.8%

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Net margin (%)
51.00% 40.90% 32.70% -385.00% -564.80% -194.90% 202020212022202320242025
Gross margin (%)
202020212022202320242025
Operating margin (%)
66.90% 54.50% 44.60% -623.80% -1091.70% -289.00% 202020212022202320242025
Return on equity (%)
14.30% 15.00% 12.90% -12.70% -15.40% -15.10% 202020212022202320242025
Shares outstanding
269.5M 318.3M 314.8M 290.8M 295.8M 300.6M 202020212022202320242025
Net debt ($)
202020212022202320242025
Share buybacks ($)
202020212022202320242025
Return on assets (%)
11.80% 11.60% 10.30% -9.80% -12.00% -10.80% 202020212022202320242025
Free cash flow margin (%)
5.60% 49.60% 42.60% -317.70% -648.40% -231.70% 202020212022202320242025
Debt / equity (×)
202020212022202320242025
EPS ($)
$0.45 $0.48 $0.50 -$0.51 -$0.55 -$0.49 202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020
Operating margin-289.0%-1091.7%-623.8%44.6%54.5%66.9%
Net margin-194.9%-564.8%-385.0%32.7%40.9%51.0%
FCF margin-231.7%-648.4%-317.7%42.6%49.6%5.6%
Return on assets-10.8%-12.0%-9.8%10.3%11.6%11.8%
Return on equity-15.1%-15.4%-12.7%12.9%15.0%14.3%
Current ratio11.329.817.338.677.707.86

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.